Oragenics Inc (OGEN): ,,,,,,,I’m out

S&P 500

US TECH 100

Dow Jones

Brent Oil

Bitcoin

Oragenics Inc (OGEN)

Reply Private New

Keep Last Read

Next 10 Prev Next

Send PM Follow Ignore

Followers	51
Posts	1829
Boards Moderated	0
Alias Born	02/12/2022

Re: None

Monday, 04/04/2022 2:56:50 PM

Monday, April 04, 2022 2:56:50 PM

,,,,,,,I’m out

Keep Last Read

Next 10 Prev Next

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:

1D
1M
3M
6M
1Y
5Y

Detailed Quote

Recent OGEN News

Form 8-K - Current report • Edgar (US Regulatory) • 07/22/2024 08:05:34 PM
Form 8-K - Current report • Edgar (US Regulatory) • 07/10/2024 12:00:30 PM
Oragenics Improves Intranasal Drug Formulation for Treating Concussed Patients • GlobeNewswire Inc. • 07/10/2024 12:00:00 PM
Oragenics Develops Automated Intranasal Device for Treating Concussed Patients • GlobeNewswire Inc. • 06/27/2024 12:30:40 PM
Oragenics, Inc. Announces Closing of Public Offering • GlobeNewswire Inc. • 06/26/2024 08:47:15 PM
Oragenics, Inc. Announces Pricing of Public Offering • GlobeNewswire Inc. • 06/25/2024 12:30:00 PM
Oragenics, Inc. Announces Proposed Public Offering • GlobeNewswire Inc. • 06/24/2024 10:43:45 PM
Form 8-K - Current report • Edgar (US Regulatory) • 06/20/2024 12:00:24 PM
Oragenics, Inc. Announces NYSE American Acceptance of Plan of Compliance • GlobeNewswire Inc. • 06/20/2024 12:00:00 PM
Form 8-K - Current report • Edgar (US Regulatory) • 05/23/2024 01:27:30 PM
Form 8-K - Current report • Edgar (US Regulatory) • 05/22/2024 12:00:17 PM
Oragenics Appoints William “Frank” Peacock MD as Chief Clinical Officer • GlobeNewswire Inc. • 05/22/2024 12:00:00 PM
Form 8-K - Current report • Edgar (US Regulatory) • 05/17/2024 12:00:41 PM
Oragenics, Inc. to Host Webinar Panel on Neurotrauma Medicine • GlobeNewswire Inc. • 05/17/2024 12:00:00 PM
Form 8-K - Current report • Edgar (US Regulatory) • 05/16/2024 12:00:22 PM
Oragenics, Inc. Prepares Intranasal Pharmaceutical, ONP-002, for Phase II Concussion Trial • GlobeNewswire Inc. • 05/16/2024 12:00:00 PM
Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2024 05:00:43 PM
Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2024 12:14:33 PM
Oragenics Partners with Avance Clinical for Phase II Concussion Trial in Australia • GlobeNewswire Inc. • 05/07/2024 12:00:00 PM
Oragenics, Inc. Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards • Business Wire • 04/19/2024 09:50:00 PM
Oragenics, Inc. Files 10K and Provides Company Update • Business Wire • 04/01/2024 01:05:00 PM
Oragenics Appoints James Kelly MD, Chief Medical Officer, to Lead Phase II Clinical Trials for Treating Concussion • Business Wire • 03/18/2024 11:00:00 AM
Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 03/06/2024 09:24:29 PM
Oragenics, Inc. Prepares Drug for Phase II Clinical Trials to Treat Concussion • Business Wire • 03/05/2024 12:45:00 PM
Oragenics Announces Closing of Public Offering • Business Wire • 03/01/2024 09:04:00 PM

More OGEN News

InvestorsHub NewsWire

Greenlite Ventures Completes Agreement with No Limit Technology • GRNL • Jul 19, 2024 10:00 AM

VAYK Expects Revenue from First Airbnb Property Starting from August • VAYK • Jul 18, 2024 9:00 AM

North Bay Resources Acquires Mt. Vernon Gold Mine, Sierra County, California, with Assays up to 4.8 oz. Au per Ton • NBRI • Jul 18, 2024 9:00 AM

Nightfood Holdings Signs Letter of Intent for All-Stock Acquisition of CarryOutSupplies.com • NGTF • Jul 17, 2024 1:00 PM

Kona Gold Beverages Reaches Out to Largest Debt Holder for Debt Purchase Negotiation • KGKG • Jul 17, 2024 9:00 AM

Avant Technologies Welcomes Back Former CEO with Eye Toward Future Growth and Expansion • AVAI • Jul 17, 2024 8:00 AM

Start posting your company's news

Only $200 per official company press release!

InvestorsHub community

Register for free to join our community of investors and share your ideas

You'll also get access to streaming quotes, interactive charts, trades, portfolio, live options flow